Zevenbergen Capital Investments LLC Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Zevenbergen Capital Investments LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 9.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 387,168 shares of the medical device company's stock after buying an additional 34,020 shares during the quarter. Zevenbergen Capital Investments LLC owned 0.10% of DexCom worth $30,110,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Congress Wealth Management LLC DE grew its position in DexCom by 865.3% in the 4th quarter. Congress Wealth Management LLC DE now owns 169,338 shares of the medical device company's stock valued at $13,170,000 after acquiring an additional 151,796 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in shares of DexCom during the fourth quarter valued at $8,197,000. KLP Kapitalforvaltning AS bought a new position in shares of DexCom in the fourth quarter worth about $10,476,000. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in DexCom by 269.4% during the 4th quarter. Teacher Retirement System of Texas now owns 28,759 shares of the medical device company's stock valued at $2,237,000 after buying an additional 20,974 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Finally, Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

DexCom Stock Down 2.5 %

NASDAQ:DXCM traded down $1.73 during mid-day trading on Friday, hitting $67.74. 4,680,803 shares of the company's stock traded hands, compared to its average volume of 4,055,859. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $141.99. The company has a market capitalization of $26.47 billion, a P/E ratio of 47.37, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a fifty day moving average of $82.32 and a 200 day moving average of $77.01.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 in the last ninety days. Company insiders own 0.30% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.